New insider activity at AbbVie ( (ABBV) ) has taken place on April 3, 2025.
Executive Vice President and Chief Commercial Officer Jeffrey Ryan Stewart recently sold 58,832 shares of AbbVie stock, amounting to a total transaction value of $12,359,504.
Recent Updates on ABBV stock
Recent developments regarding AbbVie have seen a mix of bearish and bullish sentiments. On the bearish side, there was notable put trading activity, with the Put/Call Ratio indicating a bearish outlook, possibly due to anticipation of upcoming earnings on April 25th. Conversely, Erste Group upgraded AbbVie to a Buy rating, citing the company’s robust sales growth projections and the potential for new product launches that could drive earnings per share significantly higher by 2025. Additionally, AbbVie’s announcement of positive results from the Phase 3 MIRASOL trial, showcasing significant improvements in progression-free and overall survival rates for ELAHERE in ovarian cancer treatment, has also contributed to a positive outlook. These developments have led to a raised price target by Berenberg, reflecting confidence in AbbVie’s future performance.
More about AbbVie
YTD Price Performance: 17.17%
Average Trading Volume: 6,472,110
Technical Sentiment Signal: Sell
Current Market Cap: $370.6B